Correlation of Hepatitis C Antibody Levels in Gingival Crevicular Fluid and Saliva of Hepatitis C Seropositive Hemodialysis Patients by Açıkgöz, Gökhan et al.
Hindawi Publishing Corporation
International Journal of Dentistry
Volume 2009, Article ID 247121, 5 pages
doi:10.1155/2009/247121
Clinical Study
CorrelationofHepatitis C AntibodyLevelsinGingivalCrevicular
FluidandSalivaofHepatitisCSeropositiveHemodialysisPatients
G¨ okhan Ac ¸ıkg¨ oz,1 Murat ˙ Inanc ¸C e n g i z , 1 ˙ Ilker Keskiner,1 S ¸ereftenAc ¸ıkg¨ oz,2
Murat Can,2 andAydanAc ¸ıkg¨ oz3
1Department of Periodontology, Faculty of Dentistry, Ondokuz Mayis University, Samsun, Turkey
2Department of Biochemistry, Faculty of Medicine, Karaelmas University, Zonguldak, Turkey
3Department of Oral Diagnosis and Radiology, Faculty of Dentistry, Ondokuz Mayis University, Samsun, Turkey
Correspondence should be addressed to Murat ˙ Inanc ¸C e n g i z ,dtinanc@mynet.com
Received 2 June 2009; Revised 4 July 2009; Accepted 3 August 2009
Recommended by Jukka H. Meurman
Search for hepatitis C virus (HCV) in body ﬂuids other than blood is important when assessing possible nonparenteral routes
of viral transmission. However, the role of oral ﬂuids in HCV transmission remains controversial. Our aim was to compare the
prevalence of HCV antibody (HCV Ab) levels in saliva, and gingival crevicular ﬂuid (GCF) of HCV seropositive hemodialysis
patients. Serum, saliva and GCF samples were collected from thirty-nine patients. Samples were analyzed for HCV Ab using the
Ortho HCV 3.0 SAVe enzyme-linked immunosorbent assay (ELISA). HCH Ab levels in saliva and GCF of all HCV-seropositive
patientswerestatisticallycompared.ReportedherearetheresultsofthestudydesignedtodeterminethecorrelationbetweenHCV-
RNA positivity in serum and the detection of antibodies in GCF and saliva. One hundred percent (100%) of the 39 patients have
antibodies to HCV in their serum, 15.4% have antibodies to HCV in GCF, and saliva found out. HCV Ab seropositivity in GCF
and saliva was signiﬁcantly correlated (kappa = 0.462; P<. 001). This study supports the concept that GCF may be a signiﬁcant
source of HCV in saliva.
Copyright © 2009 G¨ okhan Ac ¸ıkg¨ oz et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Hepatitis C virus (HCV) infection is associated with a
poor prognosis for survival among dialysis patients [1].
Reports on hemodialyzed patients from various countries
screened by serological assays and/or RT-PCR have shown a
prevalence of 12–29% [2]. The diagnosis of infection with
HCV is based on the detection of HCV-speciﬁc antibodies
(HCV Abs) in serum or plasma. However, during the past
decade, several authors have described the suitability of
alternative samples, such as saliva and Gingival Crevicular
Fluid (GCF). The detection rates of HCV RNA in various
studies of saliva have ranged from 0% to 100% [3–9].
The mechanism of appearence of HCV in saliva is unclear.
Although HCV is considered essentially hepatotropic, some
studies have suggested that viral replication occurs also
in peripheral Blood Mononuclear Cell (BMC) and in the
submaxillary glands [10–12]. However, possible source of
HCV in saliva may include serum exudate, that is, the
GCF and the migration of HCV-containing mononuclear
cell from periodontal inﬂammation at the dentogingival
interface into the salivary pool. There are limited studies
wich have qualitatively identiﬁed HCV in GCF; HCV RNA
was detected in 59% and 85% of GCF specimens from HCV
patients [13, 14]. Since the eﬃciency of HCV transmission
is likely related to its viral load, it is important to identify
quantitatively the viral RNA levels within the body ﬂuids
in order to properly evaluate possible nonparenteral routes
of HCV infection. However, in the general population,
periodontal disease is common and may inﬂuence the
increase of mononuclear cell excretion in GCF [15].
Several oral ﬂuid collection methods have been devel-
oped; saliva testing had a similar or better speciﬁcity than
the serum method [16]. Currently, routine diagnosis of HCV
is based on detecting antibodies (HCV Abs) in serum by
ELISA [17]. Saliva is easy to obtain, especially in outdoor2 International Journal of Dentistry
setting and in children. Thus, detecting infections using
saliva samples may be of signiﬁcant clinical, economical,
and epidemiological importance [16]. However, as the
concentration of Ig G in oral ﬂuid specimens collected by
any device may still be lower than that in serum, serological
tests originally developed for serum or plasma have been
modiﬁed to enhance their sensitivity. These modiﬁcations
include increasing the sample volume, lowering the sample
dilution, increasing the sample and conjugate incubation
times,andoptimizingthecutoﬀ.Inpr eviousstudies[18,19],
sensitivity and speciﬁcities for HCV Ab detection were 94.4–
99.1% and 98.2–99.1%, respectively, depending on the oral
ﬂuid collection and the HCV antibody screening assay used.
Although there was not a statistically signiﬁcant correla-
tion between the serum viral load and HCV level in saliva
or GCF, patients with low serum HCV loads were less likely
to have detectable HCV in their saliva. These ﬁndings have
important implications for medical personnel and suggest
that epidemiological studies designed to understand the
signiﬁcance of the oral route to transmission of HCV are
warranted [14].
The presence of HCV in the saliva has been shown in
hemodialysis patients [20, 21]. Hence, the risk of contami-
nation should be considered. Therefore, a potential source of
HCV RNA within saliva includes GCF, which might contain
HCV-infected BMC in setting of periodontal inﬂammation
[13, 14]. Also, it has been shown that rduction in lacrimal
and salivary secretion is frequent in dialysis patients [22]. To
our knowledge, there is no any study identifying HCVAb in
GCF in the patients with hemodialysis.
Thus, we examined the prevalence of antibody to HCV
in saliva and GCF of HCV seropositive hemodialysis patients
using ELISA assay in oral ﬂuid specimen as a possible
alternative to serum [16, 23].
2.MaterialsandMethods
Thirty-nine dialysis patients (22 male and 17 female)
participated in the study. All patients had been admitted
to medical and dental school clinics. Blood samples from
all patients, on hemodialysis at Ondokuz Mayis University,
Hemodialysis Center in Turkey, were taken on a monthly
basis for the detection of anti-HCV Ab, and in addition
twice per year for the detection of the presence of HCV-
RNA. Anti-HCV antibodies (HCV Abs) were analyzed using
Ortho HCV 3.0 SAVe ELISA (Ortho-Clinical Diagnostics,
Inc. Raritan, NJ). An assay commercialized for serum testing
has recently been adapted for oral ﬂuid testing, obtaining a
sensitivity and a speciﬁcity of 91.7% and 99.2%, respectively
[23]. Testing for HCV antibody (HCV Ab) in GCF and saliva
was carried out in the patients whose sera were determined
to be positive for HCV-RNA and HCV Ab. Before sample
donation, all patients provided informed consent and the
protocols were approved by the Institutional Review Board.
The patients with a history of alcoholism or exposure
to hepatotoxic drugs and presence of hepatitis B surface
antigen, antinuclear antibody and antibodies to HIV-1 and
HIV-2 and the patients having HCV-RNA positive but not
HCV Ab in serum were excluded from the study. At the
time of the study, none of the patients was receiving any
speciﬁc antiviral treatment. Liver function tests in all the
patientswerewithinnormallimits.Thepatientswereadvised
not to eat or practice oral hygiene for 2 hours prior to the
procedure.
2.1. Collecting of GCF and Saliva. Blood and saliva samples
were obtained from each patient attending the unit of
Nephrology prior to hemodialysis. Each participant donated
two-three blood and saliva samples on diﬀerent days. Blood
samples were collected in sterile tubes, and saliva samples
were obtained by asking the participant to spit into a sterile
plastic cup. GCF specimens were collected by ﬁrst drying
the gingival surface with sterile cotton, after which the area
was isolated in order to prevent contamination with saliva. A
paper strip (2 by 5mm) was then subgingivally inserted for
30 seconds to collect specimen. Saliva and GCF samples were
examinedforthepresenceofredbloodcellsbyOrthotolidine
methodexpressingpositivereactionswithdilutionsof1:100
000.[24],andprocessedimmediately.Incaseofvisibleblood
contamination, the samples were rejected and another was
taken from another site. After 30 seconds, the paper points
with absorbed ﬂuid were placed into plastic vials containing
500mL of Phosphate Buﬀered Saline (PBS) with 0.05%
Tween 20 and immediately put on the rocker for one hour at
room temperature for the elution of gingival ﬂuid. None of
thesamplescontainedblood.Blood,saliva,andGCFsamples
were centrifuged immediately at 3000rpm, for 15 minutes at
4◦C. All the samples were collected simultaneously and were
stored at –80
◦C before use.
2.2. Laboratory Methods. All serum, GCF, and saliva samples
were tested using Ortho HCV 3.0 SAVe ELISA, which detects
anti-HCV antibodies. Saliva and GCF samples with optical-
density values falling between 0.020 and 0.060 were consid-
ered indeterminate (Gray Zone) and were retested before
ﬁnal interpretation. Final values equal to or greater than
0.035 were considered positive and values lower than 0.035
negative. Serum HCV-RNA was tested by using the Cobas
Amlicor HCV 2.0 Assay (Roche Diagnostic System, Basel,
Switzerland),accordingtothemanufacturer’sinstructionsto
assess active viral replication. The lower detection limit of
this assay was 50IU/mL.
2.3.StatisticalAnalysis. Descriptivestatisticswereperformed
using the Chi-square test and its modiﬁcation, McNemar’s
Chi-square test, which was used for the paired proportions.
Statistical analysis was performed using the SPSS 11.0 pro-
gram, P values <. 05 were considered statistically signiﬁcant.
3. Results
All the patients were HCV-RNA and HCV-Ab positivity in
their serum were studied. In 74.4% of the HCV seropositive
subjects studied HCV-Ab was found to be negative in GCF
with10.3%ofthesubjectsinthegrayzoneandtheremaining
15.4% exhibiting positve results in GCF. In saliva, 79.5%
had negative, 7.7% had gray zone, and 12.8% had positiveInternational Journal of Dentistry 3
Table 1: Crosstabulation of HCV antibodies Immunoreactivity in Gingival Crevicular ﬂuid and Saliva, Kappa = 0.426; p < .001.
Gingival Crevicular ﬂuid
Positive Gray Zone Negative Total
n % n % n % n %
Saliva
Positive 2 5.1 3 7.7 5 12.8
Gray Zone 3 7.7 3 7.7
Negative 4 10.3 1 2.6 26 66.7 31 79.5
Total 6 15.4 4 10.3 29 74.4 39 100
results. In both GCF and saliva 66.7% of the subjects were
found to be negative. In 5.1% of the subjects HCV- Ab
was found to be positve. 10.3% of the subjects exhibited
positve results in GCF as 7.7% of the subjects had positve
results in their saliva. A total of 5.1% of the patients had
both HCV-Ab positive GCF and saliva, while 66.7% both
ﬂuids were HCV-Ab negative (Table 1). The correlation
coeﬃciency (kappa) between GCF and saliva HCV levels was
0.462; (P<. 001). Mc Nemar’s chi-squared test revealed no
statistically signiﬁcant diﬀerence in HCV immunopositivity
between saliva and GCF (P>. 05).
4. Discussion
There is considerable amount of evidence to suggest a
nasocomial transmission of HCV within the hemodialysis
units, although the exact modes of transmission are not fully
clariﬁed. A nasocomial transmission of HCV infection in
dialysis units has recently been documented using molecular
techniques [25]. Transmission of HCV through parenteral
exposure has been well documented. However, in 30–40%
of HCV positive patients do not have a history of parenteral
exposure [26]. Although several studies have investigated the
presence of HCV in saliva, the levels reported have varied
considerablyfrom0to100% [3–9,13,14,27–33].Thedetec-
tion of HCV-RNA is indicative of the presence of HCV parti-
cles in the saliva, thus establishing saliva as a potential carrier
of infection, conﬁrming the possibility of a nonparenteral
route of transmission for HCV. Indeed, the potential to
transmit HCV by biting has been reported in a chimpanzee
model and in humans [31–33]. In contrast to some studies,
HCV-RNA was extracted from the whole saliva [6, 34]. The
presence of HCV-RNA in some cells has been described,
although the presence of HCV-RNA in these cells did not
correlate with the presence of HCV-RNA in the serum [11].
The role of oral ﬂuids in HCV transmission remains
controversial. Although the presence of HCV-RNA in saliva
has been reported by several research groups, only limited
studies have attempted to identify HCV-RNA in saliva,
in which patients coinfected with HCV and HIV were
examined using a branched DNA assay [35]. Few studies
have investigated the occurence of human viruses in GCF
[13, 14, 36, 37]. Recently, the analysis of GCF and saliva for
the concentration of HCV-RNA revealed a higher detection
rate and greater levels of RNA in GCF versus saliva [13, 14].
ThesedatasupporttheconceptthatGCFmaybeasigniﬁcant
source of hepatitis virus in saliva.
Here, we observed HCV Ab more commonly in the GCF
than the saliva of HCV-seropositive hemodialysis patients
(Table 1). Our ﬁndings are in accordance with those of
Matiˇ ciˇ c et al. [13] and Suzuki et al. [14]. Forthermore,
we demonstrated that while the levels of HCV Ab in GCF
were slightly elevated (by 2%) above those in the saliva,
the diﬀerence was not statistically signiﬁcant (P>. 05).
As mentioned by the authors [13, 14] ,t h i sr e s u l tm a yb e
partially due to the presence of PCR inhibitors in saliva. In
studiescarriedoutbyMaticicetal.[13]andSuzukietal.[14]
which have qualitatively identiﬁed HCV in GCF and saliva,
HCV-RNA were detected 59.35% and 85.31%, respectively.
Their results were higher than ours. These discrepancies may
beduetocollectingspecimensfromGCFandsaliva.Wetried
to rule out the possible eﬀect of small amount of bleeding
as a source of HCV Ab by using Orthotolidine method
[24] but Suzuki et al. cannot rule out the possible eﬀect of
small amount of bleeding as a source of HCV-RNA [24].
Furthermore, this diﬀerence in ﬁndings may originate from
the use of volume versus concentration in measurements.
There is a continual transudation of serum into the oral
cavity through the junction of the gingival margin with the
tooth surface [15]. HCV has been widely detected in blood
mononuclear cells (BMCs) in patients with chronic HCV
infection, and the diﬀerences in quasispecies identiﬁcation
within serum and BMC suggest that viral replication occurs
within BMC [10–12, 38]. HCV infected BMC might allow
HCV to inﬁltrate the GCF and saliva. Generally, periodontal
inﬂammation increases the excretion of BMC-rich GCF.
However, no correlation was found between HCV-RNA in
saliva oral health and viral load [27, 36]. Therefore, HCV has
been identiﬁed in the mucosal tissue as well as in the salivary
glands of anti-HCV positive patients with oral lichen planus
[8].
Thus, it is likely that several possible sources discussed
above are involved in HCV penetration into the saliva and
GCF. Epidemiological studies, however, suggest that the
infective capacity of HCV viral particles in saliva is low, butit
has not been possible to determine their infective potential.
Moreover, HCV-speciﬁc receptors have not been deﬁned on
oral epithelial cells nor has the role of host defence mechan-
ims been determined. New experimental animal models
and the recently described infectious HCV pseudoparticles,
capable of simulating HCV replication in vitro, could be
useful in establishing any role of saliva in the transmission
of HCV infection [39]. However, a further investigation is4 International Journal of Dentistry
needed to understand the source of the HCV-RNA in saliva
and whether it represents an increased risk of transmission.
5. Conclusion
It is evident that patients with chronic renal disease will
comprise on enlarging proportion of the dental patients
population in the future [40]. Our study showed that HCV
AbispresentinsalivaandGCFinpatientswithhemodialysis.
Hence, practitioners need to be aware of the precautions
necessary in treating patients with hemodialysis.
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